PriceSensitive

April Psychedelic Capital investigates clinical trials & RWE & Going Mainstream

Health Care
CSE:BETR
28 April 2021 12:15 (EDT)

Microdose Psychedelic Insights, in partnership with The Conscious Fund, is pleased to present the next edition of Psychedelic Capital.

The next edition of the psychedelic investment series will be on Thursday, April 29, 2021, at 1:30 pm ET.

The PsyCap April edition will feature engaging presentations from NanoPsy, BetterLife Pharma Inc (BETR), PharmAla Biotech, as well as panel discussions on the topic of Clinical Trials & RWE and Going Mainstream: Mass Adoption.

Details and schedule of the April PsyCap are as follows: 1:45 pm, BetterLife Pharma Inc.

As the schedule that day unfolds, 3:15 pm will be dedicated to, Going Mainstream: Mass Adoption. Features Richard Skaife, Ronan Levy, Kathryn Tucker, Dustin Robinson.

“While PharmAla Biotech has a great team behind it, we’re a relatively new company,” said Nicholas Kadysh, President of PharmAla Biotech.

“I’m excited to bring our story to the PsyCap audience, and to talk with Justin Ling about what I see as the future of the industry,” added Kadysh.

Presentations are 30 minutes in length, with 10 minutes always allocated to a one-on-one Q&A session with the audience.

Psychedelic Capital features the top companies, latest IPOs, newest opportunities and deepest insights into the emerging psychedelic space.

Live networking with all the attendees is available prior to and during the event.

Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, original, evidence-based content, strategy and community. 

This online event programming is dedicated to providing investment-grade information for the nascent psychedelic sector and presents a curated group of CEOs, financial experts, thought leaders and investment luminaries from around the globe. 

BetterLife Pharma Inc. is up 7.94 per cent and is trading at C$0.68 at 11:36 am ET.

Related News